AnaptysBio, Inc. (NASDAQ:ANAB) Stock Holdings Increased by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. boosted its position in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 85.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 85,381 shares of the biotechnology company's stock after acquiring an additional 39,307 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.28% of AnaptysBio worth $1,130,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of AnaptysBio by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock worth $24,411,000 after purchasing an additional 143,584 shares in the last quarter. Fairmount Funds Management LLC acquired a new position in shares of AnaptysBio during the fourth quarter worth about $24,050,000. Boxer Capital Management LLC acquired a new position in shares of AnaptysBio during the fourth quarter worth about $17,212,000. Geode Capital Management LLC lifted its stake in shares of AnaptysBio by 4.6% during the fourth quarter. Geode Capital Management LLC now owns 486,597 shares of the biotechnology company's stock worth $6,444,000 after purchasing an additional 21,196 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its stake in shares of AnaptysBio by 41.0% during the fourth quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company's stock worth $4,428,000 after purchasing an additional 97,200 shares in the last quarter.

AnaptysBio Stock Performance

Shares of NASDAQ ANAB traded up $0.36 during midday trading on Thursday, reaching $21.17. 70,169 shares of the company's stock were exchanged, compared to its average volume of 598,641. AnaptysBio, Inc. has a 52-week low of $12.21 and a 52-week high of $41.31. The stock has a market capitalization of $621.83 million, a PE ratio of -3.48 and a beta of -0.20. The business's fifty day moving average price is $19.19 and its two-hundred day moving average price is $18.27.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.30) by $0.02. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $27.77 million for the quarter, compared to analyst estimates of $15.27 million. Analysts predict that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its Board of Directors has authorized a stock buyback plan on Monday, March 24th that permits the company to repurchase $75.00 million in shares. This repurchase authorization permits the biotechnology company to repurchase up to 13.1% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's leadership believes its shares are undervalued.

Analyst Ratings Changes

A number of brokerages have commented on ANAB. JPMorgan Chase & Co. boosted their price objective on AnaptysBio from $36.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Johnson Rice restated a "buy" rating on shares of AnaptysBio in a research note on Wednesday, March 26th. Wells Fargo & Company boosted their price objective on AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Guggenheim boosted their price objective on AnaptysBio from $52.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. Finally, Wedbush restated an "outperform" rating and set a $40.00 price objective on shares of AnaptysBio in a research note on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, AnaptysBio currently has an average rating of "Moderate Buy" and an average price target of $35.88.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.